MCID: BCT002
MIFTS: 52

Bacterial Vaginosis

Categories: Infectious diseases, Reproductive diseases

Aliases & Classifications for Bacterial Vaginosis

MalaCards integrated aliases for Bacterial Vaginosis:

Name: Bacterial Vaginosis 12 73 54 3 15 62 17 70
Vaginosis, Bacterial 44

Classifications:



External Ids:

Disease Ontology 12 DOID:3385
MeSH 44 D016585
NCIt 50 C116973
SNOMED-CT 67 237092002
UMLS 70 C0085166

Summaries for Bacterial Vaginosis

PubMed Health : 62 About bacterial vaginosis: In bacterial vaginosis (sometime abbreviated as BV) much larger numbers of bacteria grow inside of the vagina than would normally just be there. This increase in bacteria is usually not dangerous and it often goes unnoticed, but it can cause a strong-smelling vaginal discharge and be very unpleasant. It also increases the risk of a vaginal infection. Antibiotics can provide effective treatment.

MalaCards based summary : Bacterial Vaginosis, also known as vaginosis, bacterial, is related to vaginal discharge and trichomoniasis. An important gene associated with Bacterial Vaginosis is LAP3 (Leucine Aminopeptidase 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Etonogestrel and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include bone, cervix and liver, and related phenotypes are hematopoietic system and homeostasis/metabolism

Disease Ontology : 12 A vaginitis that is characterized by a grayish vaginal discharge usually of foul odor and the presence of Gardnerella vaginalis.

CDC : 3 Bacterial vaginosis (BV) is a condition that happens when there is too much of certain bacteria in the vagina. This changes the normal balance of bacteria in the vagina.

Wikipedia : 73 Bacterial vaginosis (BV) is a disease of the vagina caused by excessive growth of bacteria. Common... more...

Related Diseases for Bacterial Vaginosis

Diseases related to Bacterial Vaginosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 671)
# Related Disease Score Top Affiliating Genes
1 vaginal discharge 31.9 TNF LAP3 IL6 IL1B IL1A IL10
2 trichomoniasis 31.3 TNF LAP3 IL6 IL1B IL10 CXCL8
3 vaginitis 31.2 TNF TLR2 LAP3 IL6 IL1B IL1A
4 endometritis 31.1 TNF TLR4 TLR2 IL6 IL1B CXCL8
5 placenta disease 31.0 TNF IL6 IL1B CXCL8
6 cervicitis 30.8 TNF TLR4 IL6 IL1B IL10 DEFB4A
7 salpingitis 30.8 TNF TLR2 IL6
8 acute cystitis 30.7 TNF TLR4 IL6 IL1B IL10 CXCL8
9 cellulitis 30.7 TNF IL6 DEFB4A
10 human immunodeficiency virus infectious disease 30.5 TNF MBL2 IL4 IL10
11 chlamydia 30.3 TNF TLR4 TLR2 MBL2 IL6 IL4
12 human cytomegalovirus infection 30.3 IL6 IL1B CXCL8
13 vulvovaginal candidiasis 30.2 TLR2 MBL2 LAP3 IL4 IL1RN DEFB4A
14 candidiasis 30.2 TNF TLR4 TLR2 MBL2 IL6 IL4
15 acquired immunodeficiency syndrome 30.1 TNF IL6 IL1B IL10
16 scabies 30.1 MBL2 IL1A IL10 CXCL8
17 preterm premature rupture of the membranes 30.1 TNF TLR4 TLR2 MMP8 IL6 IL1B
18 exanthem 30.0 TNF IL6 IL1B IL10 CXCL8
19 acute gonococcal cervicitis 30.0 IL6 IL4 IL10 CXCL8
20 bacteriuria 29.9 TLR4 TLR2 PRF1 IL6 CXCL8
21 genital herpes 29.9 TLR2 PI3 IL4 IL10
22 cystitis 29.8 TNF TLR4 IL6 IL4 IL1A CXCL8
23 immune deficiency disease 29.8 TNF TLR2 MBL2 IL6 IL4 IL1B
24 oral candidiasis 29.7 LTF IL1A DEFB4A CXCL8
25 chorioamnionitis 29.7 TNF TLR4 MMP8 IL6 IL4 IL1RN
26 pyelonephritis 29.7 TNF TLR4 IL6 IL1B IL1A IL10
27 funisitis 29.6 TNF MMP8 IL6 IL1B IL10 CXCL8
28 amebiasis 29.5 TNF TLR2 IL4 IL1B IL10 CXCL8
29 pre-eclampsia 29.5 TNF TLR4 IL6 IL4 IL1B IL10
30 urethritis 29.5 TNF TLR4 TLR2 IL6 IL1B IL10
31 body mass index quantitative trait locus 11 29.3 TNF TLR4 TLR2 IL6 IL4 IL1B
32 vaginal disease 29.3 TNF TLR4 TLR2 LAP3 IL6 IL1B
33 allergic disease 29.2 TNF TLR4 TLR2 IL6 IL4 IL1B
34 disease by infectious agent 29.1 TNF TLR4 TLR2 MBL2 IL6 IL4
35 cerebral palsy 29.1 TNF TLR4 MMP8 MBL2 IL6 IL4
36 peritonitis 29.0 TNF TLR4 TLR2 MMP8 IL6 IL4
37 toxic shock syndrome 29.0 TNF TLR4 TLR2 IL6 IL4 IL1RN
38 bacterial infectious disease 28.7 TNF TLR4 TLR2 MBL2 LTF IL6
39 reactive arthritis 28.7 TNF TLR4 TLR2 MMP8 LTF IL6
40 osteoporosis 28.6 TNF TLR4 MMP8 IL6 IL4 IL1RN
41 periodontitis 28.2 TNF TLR4 TLR2 MMP8 IL6 IL4
42 lung disease 28.0 TNF TLR4 TLR2 PI3 MMP8 MBL2
43 cystic fibrosis 27.6 TNF TLR4 TLR2 PI3 MBL2 LTF
44 pelvic inflammatory disease 10.8
45 overgrowth syndrome 10.8
46 syphilis 10.6
47 infertility 10.5
48 herpes simplex 10.5
49 cervix uteri carcinoma in situ 10.5
50 cervical intraepithelial neoplasia 10.5

Graphical network of the top 20 diseases related to Bacterial Vaginosis:



Diseases related to Bacterial Vaginosis

Symptoms & Phenotypes for Bacterial Vaginosis

MGI Mouse Phenotypes related to Bacterial Vaginosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 IL10 IL1A IL1B IL1RN IL4 IL6
2 homeostasis/metabolism MP:0005376 10.24 IL10 IL1A IL1B IL1RN IL4 IL6
3 immune system MP:0005387 10.22 IL10 IL1A IL1B IL1RN IL4 IL6
4 cardiovascular system MP:0005385 10.21 IL10 IL1A IL1B IL1RN IL6 MMP8
5 integument MP:0010771 10.03 IL10 IL1A IL1B IL1RN IL4 IL6
6 liver/biliary system MP:0005370 9.81 IL10 IL4 IL6 LTF NEU1 PRF1
7 neoplasm MP:0002006 9.65 IL10 IL1A IL1B IL6 LTF MMP8
8 skeleton MP:0005390 9.36 IL10 IL1B IL1RN IL4 IL6 MBL2

Drugs & Therapeutics for Bacterial Vaginosis

PubMed Health treatment related to Bacterial Vaginosis: 62

Symptomatic bacterial vaginosis is usually treated using antibiotics to kill the germs . Treatments are available in tablet form or as a suppository or cream for direct application. Another treatment option is suppositories or capsules containing living lactic acid bacteria . These treatments are designed to protect the vaginal flora and restore the correct balance . There is not yet enough evidence on the benefits of this method. Some women also try things like putting tampons that have been soaked in tea tree oil or natural yogurt in their vagina to create a more acidic environment for the vaginal flora, but there has not yet been any research about how effective or safe these kinds of home remedies are.

Drugs for Bacterial Vaginosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
2
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
3
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
4
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
5
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
6
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
7
Norethindrone Approved Phase 4 68-22-4 6230
8
Secnidazole Approved Phase 4 3366-95-8
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Metronidazole Approved Phase 4 443-48-1 4173
11
Chlorquinaldol Approved Phase 4 72-80-0
12
Cysteine Approved, Nutraceutical Phase 4 52-90-4 5862
13
St. John's Wort Approved, Investigational, Nutraceutical Phase 4 84082-80-4
14
Norethindrone enanthate Experimental Phase 4 3836-23-5
15 Hawthorn Phase 4
16 Anti-Infective Agents Phase 4
17 Pharmaceutical Solutions Phase 4
18 Clindamycin palmitate Phase 4
19 Clindamycin phosphate Phase 4
20 Cytochrome P-450 CYP3A Inhibitors Phase 4
21 Anti-Infective Agents, Local Phase 4
22 Antifungal Agents Phase 4
23 Cytochrome P-450 Enzyme Inhibitors Phase 4
24 Respiratory System Agents Phase 4
25 Antidotes Phase 4
26 Antioxidants Phase 4
27 Protective Agents Phase 4
28 Expectorants Phase 4
29 N-monoacetylcystine Phase 4
30 Caproate Phase 4
31 Contraceptives, Oral Phase 4
32 Norethindrone Acetate Phase 4
33 Tea Phase 4
34 Tea Tree Phase 4
35 Antibiotics, Antitubercular Phase 4
36 Hormones Phase 4
37 Hormone Antagonists Phase 4
38 Estrogens Phase 4
39 Estrogens, Conjugated (USP) Phase 4
40 Contraceptive Agents Phase 4
41 Antiparasitic Agents Phase 4
42 Antiprotozoal Agents Phase 4
43
Tea tree oil Experimental, Nutraceutical Phase 4 68647-73-4
44
Formaldehyde Approved, Vet_approved Phase 3 50-00-0 712
45
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
46
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
47
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
48
Dequalinium Approved, Investigational Phase 3 6707-58-0
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
50
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
2 Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
3 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
4 The Efficacy and Safety Study of Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis Unknown status NCT03446443 Phase 4 Honghe Fujie lotion;Metronidazole Suppositories
5 The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
6 Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial Completed NCT01800825 Phase 4 Clindamycin;Placebo
7 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
8 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
9 Oral N-Acetyl Cysteine Can Prevent Preterm Labour in Multiparae With Previous Preterm Labour Completed NCT00568113 Phase 4 acetylcysteine in arm 1
10 Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda Completed NCT02905890 Phase 4 Norethisterone enantate
11 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
12 A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis Completed NCT02392026 Phase 4 Metronidazole Gel
13 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
14 Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole. Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
15 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
16 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
17 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Completed NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
18 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Completed NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
19 Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
20 A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis Completed NCT03937869 Phase 4 Secnidazole
21 Use of Vagitories Based on St. John's Wort, Tea Tree Oil and Shepherd's Purse in the Treatment of Vaginal Inflammation Completed NCT04558697 Phase 4 Shepherd's Purse extractum oleosum vagitories;Tea tree oil vagitories;Hyperici extractum oleosum vagitories;Vagitories - Probiotic
22 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
23 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT04771728 Phase 4 Metronidazole vaginal suppositories;Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)
24 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
25 Postmenopausal Pessary Users: Estrogen Versus Trimosan Recruiting NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
26 Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity Active, not recruiting NCT02432404 Phase 4 NuvaRing
27 A Randomized Controlled Trial of Treatment of Bacterial Vaginosis in Late Third Trimester to Prevent Maternal Peripartum Infection Not yet recruiting NCT04578015 Phase 4 Metronidazole;Placebo
28 The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
29 VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY. Unknown status NCT01152528 Phase 3
30 Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
31 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
32 Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
33 Single Blind Randomized Study of Efficacy and Safety of Vaginal Cream With Association of Metronidazole, Nystatin and Dexamethasone in the Treatment of Bacterial and Fungal Vaginal Infections Unknown status NCT02186145 Phase 3 Association of metronidazole; nystatin and dexamethasone;Flagyl
34 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
35 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
36 Trial of Male Circumcision: HIV, STD and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
37 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
38 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
39 Home Screening for Bacterial Vaginosis to Prevent STDs Completed NCT00667368 Phase 3 Metronidazole
40 Back to BASICS: Boric Acid, Alternate Solution for Intravaginal Colonization, Comparing Intravaginal Metronidazole to Boric Acid in Women Symptomatic for Bacterial Vaginosis Completed NCT00799214 Phase 2, Phase 3 Placebo;Boric acid;Metronidazole
41 Randomized Controlled Trial of Treatment of Male Partners of Women With BV Completed NCT02209519 Phase 3 Metronidazole (male partner)
42 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
43 A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
44 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
45 A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
46 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
47 Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial Completed NCT01160796 Phase 3 placebo;Lcr35®
48 Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
49 A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
50 A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02452866 Phase 3 SYM-1219

Search NIH Clinical Center for Bacterial Vaginosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acetic Acid
ACETIC ACID LIQUID
ACETIC ACID,GLACIAL LIQUID
CLINDAMYCIN PHOSPHATE PWDR
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
Povidone

Cochrane evidence based reviews: vaginosis, bacterial

Genetic Tests for Bacterial Vaginosis

Anatomical Context for Bacterial Vaginosis

MalaCards organs/tissues related to Bacterial Vaginosis:

40
Bone, Cervix, Liver, Skin, Eye, Placenta, Spinal Cord

Publications for Bacterial Vaginosis

Articles related to Bacterial Vaginosis:

(show top 50) (show all 4022)
# Title Authors PMID Year
1
Effect of clindamycin treatment on vaginal inflammatory markers in pregnant women with bacterial vaginosis and a positive fetal fibronectin test. 61 54
19647824 2009
2
[Benefits of Affirm VPIII and L-PAP in the diagnosis of bacterial vaginosis]. 54 61
18588815 2008
3
Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. 54 61
18462081 2008
4
MBL2 genetic screening in patients with recurrent vaginal infections. 61 54
18211540 2008
5
Among pregnant women with bacterial vaginosis, the hydrolytic enzymes sialidase and prolidase are positively associated with interleukin-1beta. 54 61
17714681 2008
6
The role of mannose-binding lectin gene polymorphisms in women with recurrent bacterial vaginosis. 61 54
17678865 2007
7
Cytokines, pregnancy, and bacterial vaginosis: comparison of levels of cervical cytokines in pregnant and nonpregnant women with bacterial vaginosis. 54 61
17922400 2007
8
Uterine cervical inflammatory cytokines, interleukin-6 and -8, as predictors of miscarriage in recurrent cases. 54 61
17845205 2007
9
Mannose-binding lectin gene polymorphism, vulvovaginal candidiasis, and bacterial vaginosis. 54 61
17470593 2007
10
Association of interleukin-1beta and interleukin-1 receptor antagonist polymorphisms with bacterial vaginosis in non-pregnant Italian women. 61 54
17314118 2007
11
Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. 54 61
18273408 2007
12
Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. 61 54
16988245 2006
13
Cervical inflammatory cytokines and other markers in the cervical mucus of pregnant women with lower genital tract infection. 61 54
16307744 2006
14
IL-1beta, IL-6 and IL-8 levels in gyneco-obstetric infections. 54 61
16338780 2005
15
Genetic variation in the interleukin-8 gene promoter and vaginal concentrations of interleukin-8 are not associated with bacterial vaginosis during pregnancy. 61 54
16038986 2005
16
Association between vaginal 70-kd heat shock protein, interleukin-1 receptor antagonist, and microbial flora in mid trimester pregnant women. 54 61
15746691 2005
17
Secondary predictors of preterm labour. 54 61
15715594 2005
18
[Correlation between levels of selected cytokines in cervico-vaginal fluid of women with abnormal vaginal bacterial flora]. 61 54
16494210 2005
19
Does bacterial vaginosis alter the sensitivity of screening tests for Chlamydia trachomatis? An analysis of patient characteristics. 54 61
12869223 2003
20
Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes. 61 54
12517887 2003
21
Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. 54 61
12529421 2003
22
Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. 54 61
12388968 2002
23
Correlation of local interleukin-8 with immunoglobulin A against Gardnerella vaginalis hemolysin and with prolidase and sialidase levels in women with bacterial vaginosis. 54 61
12023767 2002
24
Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis. 61 54
12148539 2002
25
Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. 61 54
11845812 2002
26
Vaginal indicators of amniotic fluid infection in preterm labor. 54 61
11165584 2001
27
The preterm prediction study: cervical lactoferrin concentration, other markers of lower genital tract infection, and preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. 61 54
10739520 2000
28
Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. 61 54
9815222 1998
29
IL-1beta, IL-6, TNFalpha, fetal fibronectin, and endotoxin in the lower genital tract of pregnant women with bacterial vaginosis. 61 54
9740515 1998
30
Interleukin-1alpha, interleukin-6 and interleukin-8 in cervico/vaginal secretion for screening of preterm birth in twin gestation. 54 61
9654172 1998
31
Evaluation of a fast test to identify the presence of proline aminopeptidase in women with bacterial vaginosis. 61 54
18476142 1997
32
Use of a lactoferrin assay in the differential diagnosis of female genital tract infections and implications for the pathophysiology of bacterial vaginosis. 61 54
8946639 1996
33
Correlation between the clinical diagnosis of bacterial vaginosis and the results of a proline aminopeptidase assay. 54 61
18475340 1994
34
Endotoxin and interleukin-1 alpha in the cervical mucus and vaginal fluid of pregnant women with bacterial vaginosis. 61 54
8238178 1993
35
Diagnostic microbiology of bacterial vaginosis. 54 61
8357044 1993
36
Is trichomoniasis often associated with bacterial vaginosis in pregnant adolescents? 61 54
1372472 1992
37
Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. 54 61
1551983 1992
38
A new proline aminopeptidase assay for diagnosis of bacterial vaginosis. 61 54
1892204 1991
39
Terconazole for the treatment of vulvovaginal candidiasis. 54 61
2277372 1990
40
Development and microbiological evaluation of chitosan and chitosan-alginate microspheres for vaginal administration of metronidazole. 61
33581271 2021
41
The International Society for the Study of Vulvovaginal Disease Vaginal Wet Mount Microscopy Guidelines: How to Perform, Applications, and Interpretation. 61
33631782 2021
42
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis. 61
33537666 2021
43
Isolation and Characterization of Gardnerella Phage vB_Gva_AB1, a Bacteriophage Infecting a Clinical Strain of Gardnerella vaginalis. 61
33766896 2021
44
Mucoadhesive hyaluronic acid-based films for vaginal delivery of metronidazole. 61
33675578 2021
45
The Association between Vaginal Dysbiosis and Reproductive Outcomes in Sub-Fertile Women Undergoing IVF-Treatment: A Systematic PRISMA Review and Meta-Analysis. 61
33806442 2021
46
The safety of metronidazole in pregnancy. 61
33739240 2021
47
Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study. 61
33768237 2021
48
Astodrimer gel for treatment of bacterial vaginosis: A systematic review and meta-analysis of randomized controlled trials. 61
33749959 2021
49
[Assessment of genital microbiota: An emerging approach in assisted reproductive techniques]. 61
32758671 2021
50
Current and emerging pharmacotherapy for recurrent bacterial vaginosis. 61
33750246 2021

Variations for Bacterial Vaginosis

Expression for Bacterial Vaginosis

Search GEO for disease gene expression data for Bacterial Vaginosis.

Pathways for Bacterial Vaginosis

Pathways related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF TLR4 TLR2 PI3 NEU1 MMP8
2
Show member pathways
13.73 TNF TLR4 IL6 IL4 IL1RN IL1B
3
Show member pathways
13.49 TNF TLR4 TLR2 IL6 IL4 IL1B
4
Show member pathways
13.43 TNF IL6 IL4 IL1RN IL1B IL1A
5
Show member pathways
13.35 TNF IL6 IL4 IL1B IL1A IL10
6
Show member pathways
13.29 TNF TLR4 TLR2 MBL2 IL6 IL1B
7
Show member pathways
13 TNF TLR4 TLR2 IL6 IL1B CXCL8
8
Show member pathways
12.97 TNF PRF1 IL6 IL4 IL1B IL1A
9
Show member pathways
12.93 TNF TLR4 TLR2 IL6 IL1B IL1A
10
Show member pathways
12.88 TNF TLR4 TLR2 IL4 IL1B IL1A
11
Show member pathways
12.83 TNF TLR4 TLR2 IL6 IL1B CXCL8
12
Show member pathways
12.8 TNF TLR4 TLR2 IL6 IL1B IL1A
13
Show member pathways
12.74 TNF TLR4 TLR2 IL6 IL4 IL1B
14
Show member pathways
12.73 TNF TLR4 TLR2 IL6 IL4 IL1B
15 12.68 TNF TLR2 IL4 IL1RN IL1B IL10
16
Show member pathways
12.65 TNF TLR4 TLR2 IL1B IL1A
17
Show member pathways
12.55 TNF TLR4 TLR2 IL6 IL1B CXCL8
18
Show member pathways
12.48 TNF TLR2 IL6 IL4 IL1B DEFB4A
19 12.44 TNF TLR4 IL1B CXCL8
20
Show member pathways
12.44 TNF TLR4 IL6 IL1B IL1A CXCL8
21
Show member pathways
12.43 TLR2 PI3 LTF DEFB4A DEFA5
22
Show member pathways
12.4 TNF TLR4 TLR2 IL4 IL1B IL1A
23
Show member pathways
12.39 TNF TLR4 TLR2 IL6 IL1A CXCL8
24
Show member pathways
12.39 TNF IL6 IL4 IL1B IL1A IL10
25
Show member pathways
12.38 TNF IL6 IL4 IL1B
26
Show member pathways
12.38 TNF IL6 IL10 CXCL8
27 12.38 TNF TLR4 IL6 IL1B DEFB4A DEFA5
28 12.37 TNF TLR4 TLR2 IL6 IL1B IL1A
29
Show member pathways
12.35 TNF TLR2 IL6 IL1RN IL1B IL1A
30 12.3 TNF IL6 IL1RN IL1B IL1A IL10
31
Show member pathways
12.27 TNF IL6 IL1B IL10
32
Show member pathways
12.26 TNF TLR4 IL1B IL1A
33 12.25 TNF TLR4 TLR2 IL6
34 12.23 TNF TLR4 IL6 IL1B IL10 CXCL8
35
Show member pathways
12.19 TNF TLR4 TLR2 IL6 IL4 IL1B
36
Show member pathways
12.11 TLR4 TLR2 IL1B IL1A
37 12.1 TNF TLR4 IL6 IL4 IL1B IL1A
38 12.08 TNF IL6 IL4 IL10
39 12.06 TNF IL6 IL4 IL1B IL1A IL10
40 12.05 TNF IL6 IL1B IL1A CXCL8
41 12.04 IL6 IL1B IL1A CXCL8
42 12.04 TNF IL6 IL4 IL1B IL1A
43 12.03 TNF TLR4 IL1B CXCL8
44
Show member pathways
12 TLR4 TLR2 IL6 IL4 IL1B
45 11.99 MBL2 IL10 DEFB4A DEFA5
46 11.99 TNF TLR4 TLR2 IL6 IL1B IL10
47 11.92 TNF TLR4 TLR2 IL6 IL1B IL1A
48 11.9 TNF IL4 IL1B IL10
49
Show member pathways
11.89 TNF TLR4 TLR2 IL6 IL1B IL10
50 11.86 TNF IL6 IL1B IL10

GO Terms for Bacterial Vaginosis

Cellular components related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 TNF PI3 MMP8 MBL2 LTF IL6
2 extracellular region GO:0005576 9.53 TNF PRF1 PI3 NEU1 MMP8 MBL2
3 specific granule lumen GO:0035580 9.33 NEU1 MMP8 LTF

Biological processes related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF TLR4 TLR2 IL6 IL4 IL1A
2 negative regulation of cell proliferation GO:0008285 10.12 TLR2 IL6 IL1B IL1A IL10 CXCL8
3 inflammatory response GO:0006954 10.03 TNF TLR4 TLR2 IL6 IL1RN IL1B
4 response to lipopolysaccharide GO:0032496 10.01 TLR4 TLR2 IL1B IL10
5 defense response GO:0006952 10 TNF DEFB4A DEFA5 CXCL8
6 defense response to bacterium GO:0042742 10 TNF TLR4 MBL2 LTF IL10 DEFB4A
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF TLR4 TLR2 LTF IL6 IL1B
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.97 TNF IL6 IL1B IL10
9 positive regulation of gene expression GO:0010628 9.97 TNF TLR4 TLR2 MMP8 IL6 IL4
10 positive regulation of inflammatory response GO:0050729 9.94 TNF TLR4 TLR2 IL1B
11 positive regulation of JNK cascade GO:0046330 9.93 TNF TLR4 MMP8 IL1B
12 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR4 TLR2 MMP8 IL6 IL1A
13 negative regulation of tumor necrosis factor production GO:0032720 9.92 TLR4 IL4 IL10
14 regulation of insulin secretion GO:0050796 9.92 TNF IL6 IL1B
15 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.92 LTF DEFB4A DEFA5 CXCL8
16 defense response to Gram-negative bacterium GO:0050829 9.92 TLR4 LTF IL6 DEFB4A DEFA5
17 negative regulation of interleukin-6 production GO:0032715 9.91 TNF TLR4 IL10
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL6 IL4
19 positive regulation of interferon-gamma production GO:0032729 9.91 TNF TLR4 IL1B
20 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL1RN IL10
21 antimicrobial humoral response GO:0019730 9.91 PI3 LTF DEFB4A DEFA5
22 positive regulation of T cell proliferation GO:0042102 9.9 IL6 IL4 IL1B
23 humoral immune response GO:0006959 9.9 TNF LTF IL6
24 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF TLR4 IL6
25 positive regulation of cytokine production GO:0001819 9.9 TNF IL1A IL10
26 antibacterial humoral response GO:0019731 9.89 PI3 LTF DEFA5
27 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.89 TNF TLR4 TLR2 MMP8 IL1B
28 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF TLR4 MMP8 IL1B
29 positive regulation of chemokine production GO:0032722 9.88 TNF TLR4 TLR2 IL6
30 positive regulation of interleukin-8 production GO:0032757 9.88 TNF TLR4 TLR2 IL6 IL1B
31 killing of cells of other organism GO:0031640 9.87 LTF DEFB4A DEFA5
32 acute-phase response GO:0006953 9.87 MBL2 IL6 IL1RN
33 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.86 TNF IL1B IL1A
34 positive regulation of interleukin-10 production GO:0032733 9.86 TLR4 TLR2 IL6 IL4
35 cytokine-mediated signaling pathway GO:0019221 9.86 TNF IL6 IL4 IL1RN IL1B IL1A
36 positive regulation of JAK-STAT cascade GO:0046427 9.85 TNF IL6 IL10
37 microglial cell activation GO:0001774 9.85 TNF TLR2 IL4
38 lipopolysaccharide-mediated signaling pathway GO:0031663 9.85 TNF TLR4 TLR2 IL1B
39 defense response to Gram-positive bacterium GO:0050830 9.85 TNF TLR2 MBL2 IL6 DEFB4A DEFA5
40 positive regulation of vascular endothelial growth factor production GO:0010575 9.84 IL6 IL1B IL1A
41 innate immune response in mucosa GO:0002227 9.83 LTF IL4 DEFA5
42 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
43 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TNF TLR4 IL6
44 positive regulation of glial cell proliferation GO:0060252 9.8 TNF IL6 IL1B
45 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.79 TNF IL1B IL10
46 positive regulation of MHC class II biosynthetic process GO:0045348 9.77 TLR4 IL4 IL10
47 response to molecule of bacterial origin GO:0002237 9.77 TLR2 IL10 CXCL8
48 regulation of neuroinflammatory response GO:0150077 9.75 MMP8 IL6
49 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.75 IL1RN IL10
50 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.75 TNF TLR4

Molecular functions related to Bacterial Vaginosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipopolysaccharide binding GO:0001530 9.33 TLR4 TLR2 LTF
2 lipopolysaccharide receptor activity GO:0001875 9.26 TLR4 TLR2
3 cytokine activity GO:0005125 9.23 TNF IL6 IL4 IL1RN IL1B IL1A
4 interleukin-1 receptor binding GO:0005149 9.13 IL1RN IL1B IL1A

Sources for Bacterial Vaginosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....